Navigation Links
American Orthopedic Spine Surgeon Successfully Treated for Autoimmune Arthritis with His Own Stem Cells
Date:1/26/2011

GERMANTOWN, Md., Jan. 26, 2011 /PRNewswire/ -- RNL BIO CO., LTD, a leading biopharmaceutical company specialized in adult stem cell therapeutics, announced on January 21, 2011 another successful patient report utilizing stem cell therapy on a leading US orthopedic spine surgeon who suffered from Autoimmune Arthritis.  

Dr. Stanley Jones, the surgeon and patient, reports that he had a sudden onset of acute pain in his wrist in September 2009; shortly thereafter the patient experiences pain in his knees as well.  Dr. Jones saw a rheumatologist who diagnosed him with Autoimmune Arthritis.  He was placed on Cortisone, a steroid hormone, to suppress immune response and alleviate pain.  Unfortunately Dr. Jones suffered complications from the Cortisone including chest pain and Candidiasis which were unbearable.  His condition deteriorated and his ability to perform routine activities of daily living or his profession was impacted.  

After visiting many physicians and talking with experts in the field, Dr. Jones was introduced to RNL Bio's stem cell therapy.  After a workup, he received stem cell infusions in Kyoto, Japan in May 2010.  Post infusion, he began to notice improvement and by the 5 month, he had a complete recovery and was able to resume sports as well as operating!  In addition, he no longer needed any medications including Cortisone or Methotrexate.  Dr. Jones' rheumatologist in Houston saw Dr. Jones post infusion and said, "It is amazing that Dr. Jones was able to experience improvement from cutting-edge medical technology."

Other patients treated by the company have had very successful results as reported by RNL BIO Co., Ltd in 2009, an American artist, John Cullison's stem cell treatment for Rheumatoid Arthritis, and in September 2010, Japanese Yosida's treatment for psoriasis.

About RNL BIO CO., LTD.

RNL BIO is a premier biotechnology company focused on the research and development of adult derived stem cell therapies.  RNL has two therapies in Phase II clinical trials for Buerger's Disease as well as Osteoarthritis and one phase I trial for spinal cord injury.  RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.

Video Interview Link:

http://www.youtube.com/watch?v=xzDElPr9gRo

Related Link:

http://www.rnl.co.kr/eng/main.asp


'/>"/>
SOURCE RNL BIO CO., LTD.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. American Oriental Bioengineerings CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintaos Delegation
2. Maldonado Medicals Green Initiative, a Model for the American Small Business
3. American Medical Systems Launches STEP Patient Education Program in Europe
4. American Scientific Resources, Inc. Announces S-1 Registration Statement Effective; Commences Public Reporting Requirements
5. Amarin Announces Successful Completion of Offering of American Depositary Shares
6. Amarin Prices Public Offering of American Depositary Shares
7. Pharmacists Encourage Americans to Consider Medicine Cabinet Cleanout Among New Years Resolutions
8. CVS CAREMARK to Purchase Universal Americans Medicare Part D Business
9. American Regent Initiates Nationwide Voluntary Recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%, 50 mL Single Dose Vials Due to Particulate Matter
10. Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences
11. Red Cross Supports Pan American Health Organization with $1.5 Million in Medicine and Supplies for Cholera Response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... ... is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):